-+ 0.00%
-+ 0.00%
-+ 0.00%

Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

Benzinga·10/12/2026 17:12:43
Listen to the news
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.